TSE:EVGN Evogene (EVGN) Stock Price, News & Analysis → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free EVGN Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetC$4.67 Stock AnalysisStock Analysis Get Evogene alerts: Email Address Ad Prosper Trading AcademyThis AI Trade Machine Made 1,729%* (With 89% Wins)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?Click Here To Get Your Free Copy About Evogene Stock (TSE:EVGN)Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., seed traits through the Ag-Seeds division, and ag-solutions for castor oil production through Casterra Ltd.Read More Ad Prosper Trading AcademyThis AI Trade Machine Made 1,729%* (With 89% Wins)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?Click Here To Get Your Free Copy EVGN Stock News HeadlinesApril 25, 2024 | americanbankingnews.comEvogene (TSE:EVGN) Price Target Lowered to C$4.00 at Pi FinancialApril 16, 2024 | finance.yahoo.comBiomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingApril 28, 2024 | Prosper Trading Academy (Ad)This AI Trade Machine Made 1,729%* (With 89% Wins)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?April 11, 2024 | finance.yahoo.comBiomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual MeetingApril 7, 2024 | finanznachrichten.deKursverluste für das Wertpapier von Corteva (51,32 €)March 9, 2024 | seekingalpha.comEvogene Ltd. (EVGN) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | benzinga.comIsraeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party'March 7, 2024 | washingtonpost.comEvogene: Q4 Earnings SnapshotApril 28, 2024 | Prosper Trading Academy (Ad)This AI Trade Machine Made 1,729%* (With 89% Wins)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed on Evogene’s Growth Potential and Commercial Ramp-Up in 2024February 22, 2024 | finanznachrichten.deAgPlenus Ltd.: AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive OfficerFebruary 22, 2024 | finance.yahoo.comAgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive OfficerFebruary 20, 2024 | finance.yahoo.comSyngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-InsecticideFebruary 20, 2024 | markets.businessinsider.comSyngenta Crop, Lavie Bio Partner To Discover And Develop New Biological Insecticidal SolutionsJanuary 17, 2024 | tmcnet.comBiomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology DrugJanuary 12, 2024 | finance.yahoo.comHere's Why Evogene (EVGN) is a Great Momentum Stock to BuyDecember 21, 2023 | finance.yahoo.comBiomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024November 29, 2023 | finance.yahoo.comBears are Losing Control Over Evogene (EVGN), Here's Why It's a 'Buy' NowNovember 14, 2023 | msn.comEvogene Q3 2023 Earnings PreviewOctober 18, 2023 | finance.yahoo.comEvogene Provides Operational Update Amidst Current Security Situation in IsraelOctober 14, 2023 | investing.comEvergreen Fibreboard Bhd (EVGN)October 10, 2023 | finanznachrichten.deEVOGENE LTDOctober 3, 2023 | msn.comAlliance Global Partners Initiates Coverage of Evogene (EVGN) with Buy RecommendationSeptember 27, 2023 | finance.yahoo.comCasterra Delivers First Shipment of Castor Seeds to AfricaSeptember 21, 2023 | benzinga.comWhy Evogene Shares Are MovingAugust 19, 2023 | msn.comLake Street Maintains Evogene (EVGN) Buy RecommendationAugust 2, 2023 | msn.comEvogene (EVGN) Price Target Increased by 166.67% to 4.08See More Headlines Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorManufacturing Industry Pesticide & Other Agricultural Chemical Manufacturing Sub-IndustryN/A Current SymbolTSE:EVGN CUSIPN/A CIKN/A Webwww.evogene.com PhoneN/AFaxN/AEmployees131Year FoundedN/APrice Target and Rating Average Stock Price TargetC$4.67 High Stock Price TargetC$6.00 Low Stock Price TargetC$4.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key Competitors(EDW.V)CVE:EDW(FSN.V)CVE:FSN(FTE.V)CVE:FTE108946 (AUA.V)CVE:AUA111040 (DNI.V)CVE:DNIView All Competitors EVGN Stock Analysis - Frequently Asked Questions Should I buy or sell Evogene stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EVGN shares. View EVGN analyst ratings or view top-rated stocks. What is Evogene's stock price target for 2024? 2 brokers have issued 1 year price targets for Evogene's shares. Their EVGN share price targets range from C$4.00 to C$6.00. On average, they expect the company's share price to reach C$4.67 in the next year. View analysts price targets for EVGN or view top-rated stocks among Wall Street analysts. How do I buy shares of Evogene? Shares of EVGN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:EVGN) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsUrgent Nvidia WarningAltimetryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHis win rate puts Warren Buffett to shame… Investing DailyThe A.I. story nobody is telling you (Read ASAP)TradeSmithEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
